JPRN-C000000334已完成1 期
Immunotherapy for unresectable locally advanced pancreatic cancer - Immunotherapy for pancreatic cancer
agoya University Hospital0 个研究点目标入组 5 人开始时间: 2006年2月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with immunologic abnormalities
研究者
相似试验
进行中（未招募）
1 期
aser immunotherapy with and without topical anti-PD1 in basal cell carcinomas - Laser immunotherapy and topical anti-PD1Basal cell carcinoma in 24-30 patientsEUCTR2019-003310-14-DKDepartment of Dermatology, Bispebjerg Hospital20
Enrolling By Invitation
不适用
Treatment of patients with immune-related adverse events after checkpoint inhibitors with extracorporeal photopheresis (ECP): a retrospective analysis and translational studiesImmune-related adverse events (colitis, hepatitis, dermatitis, arthralgia) after treatment with immune checkpoint inhibitors (antibodies against PD-1, PD-L1 and CTLA4).DRKS00026642niversitätsklinikum Freiburg20
招募中
2 期
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS studyBlood - Haematological diseasesMultiple MyelomaACTRN12621001037897Australasian Myeloma Research Consortium50
招募中
1 期
GcGM3/VSSP in small cell lung cancerCarcinoma, BronchogenicRespiratory Tract NeoplasmsLung NeoplasmsSmall cell lung cancerBronchial NeoplasmsSmall Cell Lung CarcinomaThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000224Center of Molecular Immunology (CIM)40
招募中
2 期
GcGM3/VSSP in Metastatic melanomaMetastatic melanomaNevi and MelanomasNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueMelanomaRPCEC00000223Center of Molecular Immunology (CIM)160